Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 30, 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform...
Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 14, 2023 16:05 ET
|
Plus Therapeutics Inc.
ReSPECT clinical trial data continues to demonstrate promise for treatment of leptomeningeal metastases and recurrent glioblastoma Received FDA approval to move into Phase 1/Part B of the ReSPECT-LM...
Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference
August 11, 2023 06:30 ET
|
Plus Therapeutics Inc.
Dose escalation trial demonstrates preliminary safety and efficacy results including median overall survival of 10 months for patients with leptomeningeal metastases FDA approves continuation to...
Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023
August 08, 2023 16:05 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference
August 08, 2023 11:22 ET
|
Plus Therapeutics Inc.
Trial investigators and company management to discuss latest data from the ReSPECT-LM leptomeningeal metastases clinical trial Webinar scheduled for Friday, August 11, 2023 at 8:00 a.m. ET AUSTIN,...
Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 03, 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations
July 27, 2023 16:05 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference
July 27, 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
July 13, 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting
June 29, 2023 07:00 ET
|
Plus Therapeutics Inc.
ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation dose ReSPECT-LM Phase 1/Part A leptomeningeal metastases trial...